ClinicalTrials.gg
RecruitingNCT07224425Updated Oct 30, 2026

A Study of BI 3810944 in Patients With Advanced Cancer

A Phase 1 interventional study of BI 3810944 in Solid Tumours and Melanoma, sponsored by Boehringer Ingelheim. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 30, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,050 studies in Melanoma with a site in United States — 244 open to participants now, 438 under way, 32 of them phase 3. Melanoma · United States.

Planned enrollment
565th of 1,750
69 · median 37
Started
2026
with 51 others
Phase 1
648 of 2,050
55 open now
Primary completion
2029-10
later than 377 of 433 live
Registered
1,994th of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 565th largest by planned enrollment of the 1,750 interventional ones that give a count, is one of 52 that started in 2026, is one of 648 in phase 1, reaches primary completion later than 377 of the 433 other live ones, and was the 1,994th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

244 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

239 more — sign in →

All 244 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults with advanced cancer (solid tumours) for whom previous treatment was not successful, or no treatment exists. The study tests different doses of BI 3810944 to find out which doses they can tolerate. Another purpose is to identify the most suitable dose of BI 3810944 and to find out whether it helps people with advanced cancer.

Participants get BI 3810944 usually once every 3 weeks. At treatment start, it is given once a week for a short time. Participants may continue to get BI 3810944 as long as they benefit from treatment. The treatment duration is planned for 2 years. During this time, they regularly visit the study site. The first study visits include overnight stays at the hospital. At the visits, study doctors check participants' health, take necessary laboratory tests, and note any unwanted effects.

The doctors also regularly check the size of the tumour with imaging methods.

03

Conditions studied

  • Solid Tumours
  • Melanoma

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Trial participant population specifically to Part A and B:

    • Part A only: participants with any or cytologically confirmed diagnosis of solid tumour who failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Participant must have exhausted available treatment options known to prolong survival for their disease.
    • Part B only: participants with histologically or cytologically confirmed diagnosis of who has progressed on, or is intolerant to available standard therapies, or for whom no standard therapy with proven benefit exists according to the local and institutional guidelines. Participants should not have received >3 (excluding prior systemic regimens received at or neoadjuvant setting and excluding treatment with tumour-infiltrating lymphocytes at any timepoint). B-raf protein kinase (BRAF) mutation status must be known prior to screening
  2. (ECOG) performance status of 0 or 1
  3. Presence of at least one outside of central nervous system (CNS) as defined per (RECIST v 1.1)
  4. Age ≥18 years
  5. Adequate organ function
  6. of ≥3 months at the start of the trial treatment in the opinion of the investigator
  7. All toxicities related to previous anticancer therapies have resolved to (CTCAE) Grade ≤1 prior to trial treatment administration (except for alopecia and peripheral neuropathy which must be CTCAE Grade ≤2 and amenorrhea/menstrual disorders which can be any Grade) Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  1. Active primary central nervous system (CNS) , active untreated and/or carcinomatous meningitis

    • Participants with asymptomatic (i.e. no clinical neurological symptoms) brain lesions are eligible provided they meet the following criteria:

      • Radiotherapy or surgery for brain metastases was completed ≥2 weeks before the first administration of BI 3810944
      • Patient is off for ≥7 days (physiologic doses of steroids are permitted), and the patient is off anti-epileptic drugs for ≥7 days or on stable doses of anti-epileptic drugs for malignant CNS disease
  2. A diagnosis of immunodeficiency; receiving chronic systemic therapy exceeding prednisone 10 mg daily or equivalent or any other form of therapy within 7 days before the step-up dose of BI 3810944
  3. Prior anticancer therapy:

    • Participants who have been treated with any other anticancer drug(s), within 28 days or within 5 half-life periods (whichever is shorter) prior to the first administration of BI 3810944
    • Participants who have been treated with extensive field radiotherapy including whole brain irradiation, within 2 weeks prior to first administration of BI 3810944
  4. Prior treatment with organ transplant or allogenic hematopoietic stem-cell transplant
  5. Anticoagulant treatment that cannot be safely interrupted based on opinion of the investigator if medically needed (e.g. )
  6. Women who are pregnant, breastfeeding or who plan to become pregnant or breastfeeding during the trial or within 4 months after the last dose of BI 3810944 Further exclusion criteria apply.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    Part A: Dose escalation

    Drug: BI 3810944

  • Experimental
    Part B: Dose expansion

    Drug: BI 3810944

Interventions

  • DrugBI 3810944

    BI 3810944

06

What researchers measure

Primary outcomes

  1. Part A (dose escalation): Occurrence of Cytokine Release Syndrome (CRS) Grade 1 or 2 during the primary Dose Limiting Toxicity (DLT) evaluation period, as a sign of minimal immunological activity that primes the immune system

    Time frame: approximately 2 months

  2. Part A (dose escalation): Occurrence of DLTs during the primary DLT evaluation period

    Time frame: approximately 2 months

  3. Part B (dose expansion): Objective Response (OR)

    OR, defined as best overall response of confirmed CR and/or confirmed PR, where best overall response is determined according to RECIST v 1.1 assessed from first treatment administration until the earliest event of PD, death or last evaluable tumour assessment during the on-treatment period before start of subsequent anticancer therapy, loss to follow up, withdrawal of consent, or end of trial.

    Time frame: up to 24 months

Secondary outcomes

  1. Part A (dose escalation): Occurrence of DLTs during the on-treatment period

    Time frame: approximately 2 months

  2. Part A (dose escalation): Occurrence of Adverse Events (AEs) (including SAEs, drug-related AEs, AESIs, and AEs leading to discontinuation of trial drug) during the on-treatment period

    Serious Adverse Events (SAEs); Adverse Event of Special Interest (AESIs).

    Time frame: approximately 2 months

  3. Part B (dose expansion): Occurrence of AEs (including SAEs, drug-related AEs, AESIs, and AEs leading to discontinuation of trial drug) during the on-treatment period

    Time frame: up to 24 months

  4. Part B (dose expansion): Duration of Response (DoR)

    DoR, defined as the time from first documented Complete Response (CR) or Partial Response (PR) until the earliest of Progressive Disease (PD) or death among trial participants with OR according to RECIST v 1.1.

    Time frame: up to 24 months

  5. Part B (dose expansion): Disease Control (DC)

    DC, defined as best overall response of confirmed CR, or confirmed PR, or Stable Disease (SD) where best overall response is defined according to RECIST v 1.1 from first treatment administration until the earliest of PD, death or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up, withdrawal of consent, or end of trial.

    Time frame: up to 24 months

  6. Part B (dose expansion): Progression-Free Survival (PFS)

    PFS, defined as the time from first administration until tumour progression according to RECIST v 1.1 or death from any cause, whichever occurs earlier.

    Time frame: up to 24 months

  7. Part A (dose escalation) and Part B (dose expansion): Maximum measured concentration of analytes in serum (Cmax)

    Time frame: up to 24 months

  8. Part A (dose escalation) and Part B (dose expansion): Area under the serum concentration-time curve over the time interval from 0 to the last measured time point, tz (AUC0-tz)

    Time frame: up to 24 months

  9. Part A (dose escalation) and Part B (dose expansion): Terminal half-life of analytes (t1/2)

    Time frame: up to 24 months

07

Study locations

5 of 7 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2029, 43 months after the start.

Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 43 months is close to that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2025
First posted
Nov 4, 2025
StartActual
Feb 24, 2026
Primary completionEst.
Oct 5, 2029
CompletionEst.
Oct 5, 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
UZ Leuven is now Recruiting
Sep 29, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedA diagnosis of immunodeficiency; receiving chronic systemic therapy exceeding prednisone 10 mg daily or equivalent or any other form of immunosuppressive therapy within 7 days before the firststep-up dose of BI 3810944
  • EditedPrior treatment with organ transplant or allogenic hematopoietic stem-cell transplant
Oct 30, 2026
Primary outcomes
2 edited, 1 description edited
What changed in the outcomes
  • EditedPart A (dose escalation): Occurrence of Cytokine Release Syndrome (CRS) Grade 1 or 2 during the Maximum Toleratedprimary Dose Limiting Toxicity (MTDDLT) evaluation period, as a sign of minimal immunological activity that primes the immune systemTime frame: approximately 2 months
  • EditedPart A (dose escalation): Occurrence of Dose Limiting Toxicity (DLTs) during the MTDprimary DLT evaluation periodTime frame: approximately 2 months
  • DescriptionPart B (dose expansion): Objective Response (OR): how it is measured was reworded
Oct 30, 2026
Secondary outcomes
7 edited, 1 description edited
What changed in the outcomes
  • EditedPart A (dose escalation): Occurrence of Adverse EventEvents (AEs) (including SAEs, drug-related AEs, AESIs, and AEs leading to discontinuation of trial drug) during the on-treatment periodTime frame: approximately 2 months
  • EditedPart B (dose expansion): Occurrence of AEs (including SAEs, drug-related AEs, AESIs, and AEs leading to discontinuation of trial drug) during the on-treatment periodTime frame: up to 24 months
  • EditedPart B (dose expansion): Disease controlControl (DC)Time frame: up to 24 months
  • EditedPart B (dose expansion): Progression-free survivalFree Survival (PFS)Time frame: up to 24 months
  • EditedPartsPart A and B (dose escalation) and Part B (dose expansion): Maximum measured concentration of BI 3810944analytes in serum (Cmax)Time frame: up to 24 months
  • EditedPartsPart A and B (dose escalation) and Part B (dose expansion): Area under the serum concentration-time curve over the time interval from 0 to the last measured time point, tz (AUC0-tz)Time frame: up to 24 months
  • EditedPartsPart A and B (dose escalation) and Part B (dose expansion): Terminal half-life of BI 3810944analytes (t1/2)Time frame: up to 24 months
  • DescriptionPart B (dose expansion): Duration of Response (DoR): how it is measured was reworded
Oct 30, 2026
Show all 2 updates
  1. Oct 30, 2026
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedA diagnosis of immunodeficiency; receiving chronic systemic therapy exceeding prednisone 10 mg daily or equivalent or any other form of immunosuppressive therapy within 7 days before the firststep-up dose of BI 3810944
    • EditedPrior treatment with organ transplant or allogenic hematopoietic stem-cell transplant
    Primary outcomes 2 edited, 1 description edited
    What changed in the outcomes
    • EditedPart A (dose escalation): Occurrence of Cytokine Release Syndrome (CRS) Grade 1 or 2 during the Maximum Toleratedprimary Dose Limiting Toxicity (MTDDLT) evaluation period, as a sign of minimal immunological activity that primes the immune systemTime frame: approximately 2 months
    • EditedPart A (dose escalation): Occurrence of Dose Limiting Toxicity (DLTs) during the MTDprimary DLT evaluation periodTime frame: approximately 2 months
    • DescriptionPart B (dose expansion): Objective Response (OR): how it is measured was reworded
    Secondary outcomes 7 edited, 1 description edited
    What changed in the outcomes
    • EditedPart A (dose escalation): Occurrence of Adverse EventEvents (AEs) (including SAEs, drug-related AEs, AESIs, and AEs leading to discontinuation of trial drug) during the on-treatment periodTime frame: approximately 2 months
    • EditedPart B (dose expansion): Occurrence of AEs (including SAEs, drug-related AEs, AESIs, and AEs leading to discontinuation of trial drug) during the on-treatment periodTime frame: up to 24 months
    • EditedPart B (dose expansion): Disease controlControl (DC)Time frame: up to 24 months
    • EditedPart B (dose expansion): Progression-free survivalFree Survival (PFS)Time frame: up to 24 months
    • EditedPartsPart A and B (dose escalation) and Part B (dose expansion): Maximum measured concentration of BI 3810944analytes in serum (Cmax)Time frame: up to 24 months
    • EditedPartsPart A and B (dose escalation) and Part B (dose expansion): Area under the serum concentration-time curve over the time interval from 0 to the last measured time point, tz (AUC0-tz)Time frame: up to 24 months
    • EditedPartsPart A and B (dose escalation) and Part B (dose expansion): Terminal half-life of BI 3810944analytes (t1/2)Time frame: up to 24 months
    • DescriptionPart B (dose expansion): Duration of Response (DoR): how it is measured was reworded
    + 2 other changes: verification date and description
  2. Sep 29, 2026
    UZ Leuven is now Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07224425
Responsible party
Sponsor
First posted
Nov 4, 2025
Start date
Feb 24, 2026
Primary completion
Oct 5, 2029 (estimated)
Completion
Oct 5, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion